|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
gptkb:various_countries
|
|
gptkbp:administration_schedule
|
3 weeks apart
|
|
gptkbp:approves
|
gptkb:Russia
|
|
gptkbp:average_temperature
|
-18° C
|
|
gptkbp:clinical_trial
|
over 40,000
multiple countries
Phase III
|
|
gptkbp:clinical_trial_results_published
|
February 2021
|
|
gptkbp:developed_by
|
Gamaleya Research Institute
|
|
gptkbp:distribution
|
over 70 countries
|
|
gptkbp:dosage_form
|
2
yes
|
|
gptkbp:efficacy_study_published_in
|
gptkb:The_Lancet
|
|
gptkbp:first_dose_efficacy
|
91.6%
|
|
gptkbp:funding
|
government and private sources
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sputnik V vaccine
|
|
gptkbp:is_vulnerable_to
|
gptkb:virus
gptkb:significant
ongoing
affordable
logistical issues
strong immune response
limited in some regions
continuing for new variants
reduction in COVID-19 cases
against severe disease
adverse event monitoring ongoing
repurposed adenoviral vector
|
|
gptkbp:manufacturer
|
Russian Direct Investment Fund
|
|
gptkbp:market
|
ongoing
|
|
gptkbp:origin
|
gptkb:Sputnik_satellite
|
|
gptkbp:partnerships
|
various pharmaceutical companies
|
|
gptkbp:public_perception
|
mixed
|
|
gptkbp:regulatory_compliance
|
multiple countries
|
|
gptkbp:release_date
|
August 2020
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:second_dose_efficacy
|
91.6%
|
|
gptkbp:side_effect
|
fatigue
headache
fever
injection site pain
|
|
gptkbp:storage_stability
|
up to 6 months at -18° C
|
|
gptkbp:targets
|
gptkb:COVID-19
|
|
gptkbp:type
|
viral vector vaccine
|
|
gptkbp:vaccine_acceptance
|
varies by region
|
|
gptkbp:vaccine_approval_process
|
fast-tracked in some countries
|
|
gptkbp:vaccine_clinical_trial_phases
|
completed Phase I, II, III
|
|
gptkbp:vaccine_distribution_partners
|
international organizations
|
|
gptkbp:vaccine_efficacy_against_variants
|
studied
|
|
gptkbp:vaccine_ethical_considerations
|
discussed in public forums
|
|
gptkbp:vaccine_global_health_impact
|
considerable
|
|
gptkbp:vaccine_herd_immunity_contribution
|
gptkb:magical_abilities
|
|
gptkbp:vaccine_public_awareness_campaigns
|
implemented in various countries
|
|
gptkbp:vaccine_regulatory_challenges
|
faced in some regions
|
|
gptkbp:vaccine_research_collaborations
|
with global health organizations
|
|
gptkbp:whoapproval_status
|
Emergency Use Listing
|
|
gptkbp:bfsParent
|
gptkb:COVID-19_pandemic_in_Iran
|
|
gptkbp:bfsLayer
|
7
|